Generic Medicine Info
Concurrent use w/ halogenated hydrocarbon anaesth.
Special Precautions
Patient w/ HTN, DM, heart or thyroid diseases, cirrhosis. May provoke relapse in patients w/ history of malaria. Monitoring Parameters Monitor BP.
Adverse Reactions
HTN, headache, tachycardia. Rarely, abscess formation, tissue necrosis, sloughing.
Potentially Fatal: Ventricular arrhythmia (in patient w/ Laennec's cirrhosis).
Drug Interactions
Increased action w/ MAOI and TCA. Decreased pressor effect w/ α-adrenergic blockers. May cause ectopic arrhythmia w/ digitalis.
CIMS Class
ATC Classification
C01CA09 - metaraminol ; Belongs to the class of adrenergic and dopaminergic cardiac stimulants excluding glycosides. Used in the treatment of heart failure.
Disclaimer: This information is independently developed by CIMS based on metaraminol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in